Tirzepatide Bigger Results, Bigger Buzz Why it's popular: Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist that outperformed semaglutide head-to-head, reaching about 20.9% weight loss in SURMOUNT-1 ( Jastreboff et al., NEJM 2022 )
When were young, were asked by older men, show me your bicep. As adults we compare how much we can bench or how much we can squat
Image: Galina Zhigalova/Getty Images About the Author Maureen Salamon, Executive Editor, Harvard Women's Health Watch About the Reviewer Meghan Salamon, MS, RDN, LDN, CPT, Contributor Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
This requires a team approach from neurologists and psychiatrists to manage different aspects of the disease 5